Aclaris Therapeutis (ACRS) PT Lowered to $34 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Aclaris Therapeutics (ACRS) Prices 8.6645M Share Common Offering at $10.75/Sh
October 18, 2018 5:45 AM EDTAclaris Therapeutics, Inc. (NASDAQ: ACRS) today announced the pricing of its underwritten public offering of 8,645,000 shares of its common stock at a price to the public of $10.75 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to... More
Aclaris Therapeutics (ACRS) Announces Proposed Common Share Offering
October 17, 2018 4:01 PM EDTAclaris Therapeutics, Inc. (Nasdaq: ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient needs in aesthetic and medical dermatology and immunology, today announced that it intends to offer and sell, subject to market... More
